Toggle navigation
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
2024 SABCS
Thematic Newsreels
2024 ASH Annual Meeting
RSNA 2024 Annual Meeting
2024 JADPRO Live
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Cardio-oncology
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
Advertisement
Departments
ASCO Plenary Series
Adolescent and Young Adult Oncology
Announcements
Art of Oncology
ASCO State Affiliates
At Microphone 1
The Big Casino
Book Reviews
Clinical Trials Resource Guide
Direct From ASCO
Diversity in Oncology
Education in Oncology
End-of-Life Oncology
Expert’s Corner
FDA Update
Geriatrics for the Oncologist
Health-Care Policy
Hematology Expert Review
In Memoriam
Inside the Black Box
Integrative Oncology
In the Clinic
In the Literature
In the News
Journal Spotlight
Law and Ethics
Letters to the Editor
Living a Full Life
OCE Insights
Oncology Worldwide
Perspectives
Palliative Care in Oncology
Patient’s Corner
Pioneers in Oncology
Prevention in Oncology
Profiles
Psychosocial Oncology
Special Reports
Through the Lens of Oncology History
View From The Top
Women in Oncology
Advertisement
Advertisement
Dec
24
Today In Oncology
Combination of Two Oral Agents May Improve Progression Free Survival in Patients With Previously Untreated CLL
Primary Analysis of ZUMA-2: Treatment of BTK Inhibitor–Naive Relapsed/Refractory Mantle Cell Lymphoma
Primary Analysis of ZUMA-2 Treatment of BTK Inhibitor-Naive Relapsed Refractory Mantle Cell Lymphoma
FDA Grants Accelerated Approval to Encorafenib Combination for BRAF V600E–Mutant Metastatic Colorectal Cancer
SEQUOIA 5-Year Follow-up Zanubrutinib vs Bendamustine/Rituximab in Treatment-Naive CLL/SLL
View More
Advertisement